Google launched a 99 dollar screenless fitness tracker and a 9.99 dollar per month AI health coach powered by Gemini. One day later, Whoop announced that it would add on-demand video consultations with licensed clinicians to its app. Google is betting that artificial intelligence can interpret your health data. Whoop is betting that you still need a doctor. The US Food and Drug Administration, which relaxed its oversight of both AI health tools and consumer wearables in January, is betting that neither needs much regulation.

The sequence is not a coincidence. It is a philosophical split in the wearable health industry, articulated in product announcements issued 24 hours apart. The question both companies are answering is the same: what should happen after the sensor on your wrist collects the data? Google’s answer is an AI chatbot. Whoop’s answer is a human with a medical licence. The market will decide which one people trust with their bodies.

The tracker

The Fitbit Air is a screenless band that costs 99 dollars. It is the smallest Fitbit ever made. It tracks heart rate, heart rate variability, SpO2, sleep stages, and activity continuously, with a battery life of approximately one week. It has no display. All data is accessed through the new Google Health app, which replaces the Fitbit app on 19 May.

The device ships on 26 May with a three-month free trial of Google Health Premium, which costs 9.99 dollars per month or 99 dollars per year. The premium tier includes the Google Health Coach, an AI assistant built on Gemini that generates personalised workout plans, interprets sleep trends, summarises health records, and answers questions about a user’s fitness and medical data.

Google’s strategy is not to sell hardware. It is to sell the AI layer on top of the data. The Google Health app is designed to be wearable-agnostic, with planned support for Apple Watch, Oura, and Garmin devices later this year. The Fitbit Air is the entry point, not the destination. Google wants to be the intelligence that sits between every wearable sensor and every health decision, regardless of which device collected the data.

The response

Whoop’s announcement arrived on 8 May, exactly one day after Google’s. The company will offer on-demand video consultations with licensed clinicians through its app for users in the United States, launching this summer. The consultations begin with a review of the user’s continuous biometric data collected by the Whoop band. If the user has synced blood work or medical history through HealthEx, an electronic health records integration that Whoop is also launching, that information is included.

The distinction from Google’s approach is deliberate. A clinician can ask follow-up questions, identify patterns that require context a chatbot does not have, and carry the professional accountability that comes with a medical licence. An AI coach can tell you your heart rate variability is trending down. A doctor can tell you why.

Blossom Health raised 20 million dollars to put AI copilots alongside psychiatrists, a model that treats AI as support for clinicians rather than a replacement for them. Whoop is applying the same logic to wearable health data: the AI processes the numbers, but a human makes the call.

Will Ahmed, Whoop’s founder and chief executive, posted an image on X of a Whoop circuit board with the words “Don’t bother copying us, we will win” engraved on it. The message was originally aimed at Amazon, which launched and subsequently killed the Halo fitness band. It now reads as a response to a company with considerably more resources than Amazon’s wearables division.

The economics

Whoop raised 575 million dollars in March 2026 at a valuation of 10.1 billion dollars, with investors including the Qatar Investment Authority, Mubadala, Abbott, and the Mayo Clinic. The company reported 1.1 billion dollars in annualised revenue in 2025, up 103 per cent year over year, and said it was cash-flow positive. It has more than 2.5 million members.

Whoop’s subscription costs between 199 and 359 dollars per year depending on the tier. Google Health Premium costs 99 dollars per year. The Fitbit Air costs 99 dollars. A year of Fitbit Air plus Google Health Premium costs less than a year of Whoop’s cheapest plan. The clinician consultations that Whoop is adding will cost extra, with pricing not yet announced.

The price gap frames the competitive question. Google is offering AI health coaching at a price point that undercuts Whoop’s subscription by more than half. Whoop is offering human medical consultations at a price that will push its total cost higher. One company is driving the cost of health guidance toward zero. The other is arguing that the value of a human clinician justifies a premium. Both positions are coherent. Neither has been tested at scale in the wearable market.

The field

ChatGPT Health launched in January 2026, connecting Apple Health data to OpenAI’s models. Microsoft followed a week later with Copilot Health. Perplexity launched Perplexity Health, pulling together electronic health records, wearable data, and lab results into a single AI-powered dashboard. Amazon opened its Health AI to all US customers, backed by its One Medical clinical network and pharmacy.

Every major AI platform now has a health product. The wearable data that Fitbit, Whoop, Apple Watch, and Oura collect has become the input for a competition between AI models, each promising to turn continuous biometric monitoring into personalised health advice. The differentiation is not in the data. Heart rate, sleep stages, and SpO2 are measured by every device on the market. The differentiation is in what happens next.

Corti’s Symphony AI outperformed models from OpenAI and Anthropic on medical coding benchmarks, demonstrating that specialised health AI can exceed general-purpose models on clinical tasks. The implication for the wearable market is that the AI interpreting your health data may matter more than the sensor collecting it. Google is building that AI into a consumer subscription. Whoop is routing around it to a human.

The regulation

In January 2026, the FDA updated two guidance documents that collectively loosened oversight of both consumer wearables and AI-enabled health tools. The General Wellness Guidance clarified that low-risk wellness devices using optical sensing to estimate physiological parameters, which describes every screenless fitness tracker on the market, can be sold without premarket review as long as they make wellness claims rather than clinical ones. The Clinical Decision Support Guidance softened the agency’s approach to AI tools that help users navigate diagnoses and health decisions.

The regulatory shift creates space for both Google and Whoop. Google’s AI health coach can offer personalised guidance without triggering medical device classification, provided it frames its outputs as wellness advice. Whoop’s clinician consultations operate under existing telemedicine frameworks. The FDA’s position is that neither the AI chatbot nor the wearable sensor requires the level of scrutiny applied to medical devices, as long as neither claims to diagnose or treat disease.

The gap between what these products do and what they claim to do is where the regulatory question lives. An AI coach that tells a user their recovery score suggests they should rest is wellness advice. An AI coach that tells a user their heart rate variability pattern is consistent with early atrial fibrillation is a clinical claim. The line between the two is a sentence, and the incentive to cross it increases with every subscription dollar at stake.

Google built a 99 dollar tracker and a 9.99 dollar AI coach. Whoop is adding doctors to an app attached to a 10 billion dollar company. The FDA says both are fine. The user strapping a screenless band to their wrist and asking what their data means will not be choosing between two products. They will be choosing between two theories of what health data is for: a prompt for an algorithm, or a conversation with a person who went to medical school.